Halozyme Therapeutics (HALO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.34 +1.34%
EPS Growth %: +32.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
ARIS, COHR, ATS, More
EPS Growth %: +32.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
ARIS, COHR, ATS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $31.43 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $115-125 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Power Integrations (POWI) Tops Q3 EPS by 5c; Offers Guidance
- Progyny (PGNY) Tops Q3 EPS by 21c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
